Check out which companies are making headlines before the bell:

Eli Lilly — The drugmaker said its experimental Alzheimer's drug failed to meet its goals in a phase 3 study, with no significant slowdown in memory loss. Lilly will abandon efforts to bring the drug to market as a result.